The Cell and Gene Therapy Access Model — A Vision for Future Development

11th Mar, 2026

Hematology/Oncology

The New England Journal of Medicine

The CMS Innovation Center is approaching the next negotiation cycle for the CGT Access Model. Several considerations will guide the selection of future candidate diseases and potential new model designs.

Published By: The New England Journal of Medicine

Hematology/Oncology

11th Mar, 2026

The New England Journal of Medicine

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer

Hematology/Oncology

11th Mar, 2026

The New England Journal of Medicine

Heads or the Tail?

Hematology/Oncology

11th Mar, 2026

The New England Journal of Medicine

Biting the Tail of CAR-T for Relapsed Multiple Myeloma

Hematology/Oncology

11th Mar, 2026

The New England Journal of Medicine

Gene Therapy for Nephropathic Cystinosis

Hematology/Oncology

11th Mar, 2026

The New England Journal of Medicine

Hematopoietic Stem-Cell Gene Therapy for Cystinosis

Hematology/Oncology

11th Mar, 2026

The New England Journal of Medicine

Hitting the Mark — Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer

Hematology/Oncology

11th Mar, 2026

The New England Journal of Medicine

The Cell and Gene Therapy Access Model — A Vision for Future Development

Related Articles

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer

Heads or the Tail?

Biting the Tail of CAR-T for Relapsed Multiple Myeloma

Gene Therapy for Nephropathic Cystinosis

Hematopoietic Stem-Cell Gene Therapy for Cystinosis

Hitting the Mark — Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer

Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors

The Cell and Gene Therapy Access Model — A Vision for Future Development

Related Articles

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer

Heads or the Tail?

Biting the Tail of CAR-T for Relapsed Multiple Myeloma

Gene Therapy for Nephropathic Cystinosis

Hematopoietic Stem-Cell Gene Therapy for Cystinosis

Hitting the Mark — Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer

Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors